Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any ...
The fund, with its quality characteristics, underperformed its benchmark for the quarter and the year. Read more here.
Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...
Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results